The Promise of Better Treatments for Chronic Leukemia

Published on

Loading the player...
Topics include: Treatment

This Special Edition of Patient Power took place live from the annual American Society of Hematology (ASH) meeting in San Francisco. While there, Andrew caught up with his own physician, Dr. Michael Keating, to discuss the latest news in chronic lymphocytic leukemia (CLL), the condition he has lived with for 12 years. Dr. Keating is a professor of medicine and well known worldwide as a CLL expert from The University of Texas M. D. Anderson Cancer Center in Houston.

The program begins with Andrew reminding listeners of his story and how the treatment that he received in a clinical trial eight and a half years ago, fludarabine cyclophosphamide rituximab (FCR), is now the standard of care for most with CLL. Dr. Keating goes on to explain that particular regimen and begins a discussion of the newer clinical trials. This year the biggest studies that have ever been put together for CLL are taking place. Dr. Keating talks about these trials and the promising new medicines on the horizon.

In this program you’ll hear the latest breaking news in CLL. Dr. Keating answers listener questions about what happens when CLL returns and how the immune system may be restored through transplant. Learn how doctors from around the world are partnering together to win the fight against CLL. If you’re searching for current and in-depth information on chronic lymphocytic leukemia, don’t miss this special edition program.

View more programs featuring

Produced in association with

Related Programs

CLL Therapy Increasing Survival

Dr. Michael Keating discusses the extended data and therapeutic challenges surrounding CLL.

Beyond FCR for CLL Patients

Dr. Jose Leis talks about alternative CLL treatment options for non-responsive FCR patients.

Good News for CLL Treatment: Your Questions Answered

Dr. William Wierda talks about the good news in treatment for CLL patients.

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on